WO1998018430A3 - P2y receptor antagonists - Google Patents

P2y receptor antagonists Download PDF

Info

Publication number
WO1998018430A3
WO1998018430A3 PCT/US1997/019922 US9719922W WO9818430A3 WO 1998018430 A3 WO1998018430 A3 WO 1998018430A3 US 9719922 W US9719922 W US 9719922W WO 9818430 A3 WO9818430 A3 WO 9818430A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
receptor
antagonists
utp
atp
Prior art date
Application number
PCT/US1997/019922
Other languages
French (fr)
Other versions
WO1998018430A2 (en
Inventor
Jose L Boyer
T Kendall Harden
Kenneth A Jacobson
Emidio Camaioni
Original Assignee
Univ North Carolina
Jose L Boyer
T Kendall Harden
Kenneth A Jacobson
Emidio Camaioni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Jose L Boyer, T Kendall Harden, Kenneth A Jacobson, Emidio Camaioni filed Critical Univ North Carolina
Priority to JP52080798A priority Critical patent/JP2001504097A/en
Priority to AU55846/98A priority patent/AU5584698A/en
Priority to EP97952172A priority patent/EP0929218A4/en
Publication of WO1998018430A2 publication Critical patent/WO1998018430A2/en
Publication of WO1998018430A3 publication Critical patent/WO1998018430A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

Novel P2Y receptor antagonists derived from ATP and UTP are described. P2Y receptor antagonists with competitive antagonist activity at the P2Y receptor are described in particular, as are P2Y receptor antagonists that bind selectively to the P2Y1 receptor. Also described herein are methods of detecting a P2Y receptor in a biological sample.
PCT/US1997/019922 1996-10-30 1997-10-23 P2y receptor antagonists WO1998018430A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP52080798A JP2001504097A (en) 1996-10-30 1997-10-23 P2Y receptor antagonist
AU55846/98A AU5584698A (en) 1996-10-30 1997-10-23 P2y receptor antagonists
EP97952172A EP0929218A4 (en) 1996-10-30 1997-10-23 P2y receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2985596P 1996-10-30 1996-10-30
US60/029,855 1996-10-30

Publications (2)

Publication Number Publication Date
WO1998018430A2 WO1998018430A2 (en) 1998-05-07
WO1998018430A3 true WO1998018430A3 (en) 1998-06-18

Family

ID=21851254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/019922 WO1998018430A2 (en) 1996-10-30 1997-10-23 P2y receptor antagonists

Country Status (5)

Country Link
EP (1) EP0929218A4 (en)
JP (1) JP2001504097A (en)
AU (1) AU5584698A (en)
CA (1) CA2241687A1 (en)
WO (1) WO1998018430A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1058686B1 (en) 1998-02-25 2006-11-02 Emory University 2'-fluoronucleosides
SE9802574D0 (en) * 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
WO2001007054A1 (en) * 1999-07-22 2001-02-01 Supergen, Inc. Methods for treating autoimmune diseases
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
WO2002062816A1 (en) * 2001-02-07 2002-08-15 Celltech R & D Limited Non-natural nucleotides and dinucleotides
WO2003039473A2 (en) * 2001-11-06 2003-05-15 Inspire Pharmaceuticals, Inc. Method for treating or preventing inflammatory diseases
KR20050097971A (en) * 2003-02-03 2005-10-10 씨브이 쎄러퓨틱스, 인코포레이티드 Partial and full agonists of a1 adenosine receptors
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2005113511A1 (en) * 2004-05-12 2005-12-01 Bristol-Myers Squibb Company Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2006078621A2 (en) 2005-01-19 2006-07-27 Bristol-Myers Squibb Company 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
EP1899299B1 (en) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
KR20080027890A (en) * 2005-06-27 2008-03-28 브리스톨-마이어스 스큅 컴퍼니 N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP2367837B1 (en) 2006-11-17 2016-08-17 MicroDose Therapeutx, Inc. 1'-substituted ribose 5'-polyphosphate analogs and their use as modulators of p2y receptor activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788181A (en) * 1986-09-29 1988-11-29 The United States Of America As Represented By The Department Of Health And Human Services 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2122529A1 (en) * 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphate analogs of the nucleoside di and tnphosphate and processes for their preparation
JPS4911896A (en) * 1972-05-15 1974-02-01
DE2331223C2 (en) * 1972-06-19 1984-11-22 Kohjin Co., Ltd., Tokio / Tokyo S-substituted-2-thioadenosines, their 5'-monophosphates, processes for their preparation and pharmaceuticals containing them
US4266048A (en) * 1977-10-11 1981-05-05 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of analogs of 3'-phosphoadenosine 5'-phosphosulfate (PAPS)
US4828979A (en) * 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4719295A (en) * 1985-12-31 1988-01-12 Warner-Lambert Company Compound 2-iodo-2'-deoxyadenosine
EP0508687B1 (en) * 1991-04-06 1995-09-13 Astra Pharmaceuticals Limited ATP analogues
JP3083156B2 (en) * 1993-02-10 2000-09-04 アストラ・フアーマシユウテイカルズ・リミテツド N-alkyl-2-substituted ATP analogs
WO1995010287A1 (en) * 1993-10-15 1995-04-20 Wisconsin Alumni Research Foundation Substituted purine nucleoside analogs and method for treating endotoxin shock
US5712258A (en) * 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788181A (en) * 1986-09-29 1988-11-29 The United States Of America As Represented By The Department Of Health And Human Services 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BR. J. PHARMACOL., 1996, Vol. 118, No. 8, BOYER J.L. et al., "Identification of Potent P2Y-Purinoceptor Agonists that are Derivatives of Adenosine 5'-Monophosphate", pages 1959-1964. *
CHEMICAL ABSTRACTS, Abstract No. 126:43223, FAN J. et al., "DNA Sequencing with (.alpha.33-P)-Labelled ddNTP Terminators: A New Approach to DNA Sequencing with Thermo Sequenase DNA Polymerase"; & BIOTECHNIQUES, 1996, Vol. 21, No. 6, pages 1132-1137. *
DRUG DESIGN AND DISCOVERY, 1995, Vol. 13, VANRHEE et al., "Modelling the P2Y Purinoceptor Using Rhodopsin as Template", pages 133-154. *
PHARMACOLOGY TOXICOLOGY, 1995, Vol. 76, SIMON J. et al., "Characterization of P2Y Purinoceptor in Brain", pages 302-307. *
See also references of EP0929218A4 *

Also Published As

Publication number Publication date
EP0929218A2 (en) 1999-07-21
EP0929218A4 (en) 2001-05-16
CA2241687A1 (en) 1998-05-07
JP2001504097A (en) 2001-03-27
WO1998018430A2 (en) 1998-05-07
AU5584698A (en) 1998-05-22

Similar Documents

Publication Publication Date Title
WO1998018430A3 (en) P2y receptor antagonists
CA2078572A1 (en) Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
IS5860A (en) 4,4-barylpiperidine derivatives with opioid receptor activity
NO994972D0 (en) Polymer blends with improved elongation
ATE242243T1 (en) CYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACHYKINE RECEPTOR ANTAGONISTS
DZ2320A1 (en) Vitronectin receptor antagonists.
BR9707391A (en) Pyrazolpyrimidines as crf receptor antagonists
WO2003047420A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
ATE201016T1 (en) PYRIMIDINDIONE, PYRIMIDINDRION, TRIAZINDIONE DERIVATIVES AS ALPHA-1 ADRENERGIC RECEPTOR ANTAGONISTS
DK0920438T3 (en) N6 heterocyclic-substituted adenosine derivatives
NO20002800D0 (en) Cyclosporin-containing microemulsion, preconcentrate composition
ES2175066T3 (en) VASOPRESINE TRICYCLE ANTAGONISTS.
DE69728392D1 (en) INDOLDER DERIVATIVES USED AS ENDOTHELINE RECEPTOR ANTAGONISTS
WO2002046766A3 (en) Bioanalytical reagent, method for production thereof, sensor platforms and detection methods based on use of said bioanalytical reagent
NO975976D0 (en) Vitronectin receptor antagonists, preparation and use thereof
DE69017063T2 (en) Engine monitor, equipped with knock detector.
MA23172A1 (en) ENDOTHELIN RECEPTOR ANTAGONISTS.
NO991079D0 (en) Azinyloxy and phenoxy-diaryl-carboxylic acid derivatives, their preparation and their use as leafy ETA / ETB endothelin receptor antagonists
TR199600359A2 (en) Adhesion receptor antagonists.
NO975975D0 (en) Vitronectin receptor antagonists, preparation and use thereof
AU1178100A (en) Novel g protein-coupled receptor protein, its dna and ligand thereof
DE50008020D1 (en) SUBSTITUTED PYRROLIDIN-2,3,4-TRION DERIVATIVES EFFECTIVE AS NMDA RECEPTOR ANTAGONISTS
DE69832897D1 (en) POLYACETAL COMPOSITION WITH IMPROVED TOUGHNESS
ID24819A (en) HERTHICICLIC SUBSTITUTION, MAKING AND USING IT AS ENDOTELINE RECEPTOR ANTAGONISTS
DZ3204A1 (en) Streptogramin derivatives, their preparation and the compositions containing them.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI GB GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI GB GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR

ENP Entry into the national phase

Ref document number: 2241687

Country of ref document: CA

Ref country code: CA

Ref document number: 2241687

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 55846/98

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 520807

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997952172

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

WWP Wipo information: published in national office

Ref document number: 1997952172

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997952172

Country of ref document: EP